Biomarker Analysis Services for Polycythemia Vera
At Protheragen, we offer specialized biomarker analysis services tailored for Polycythemia Vera research and drug discovery. Our comprehensive biomarker panel is designed to advance the understanding of Polycythemia Vera pathophysiology and support the development of novel therapeutics. All services are exclusively focused on drug discovery through preclinical development stages and do not include any clinical diagnostic offerings.
The foundation of effective therapeutic intervention lies in the robust discovery and identification of disease-relevant biomarkers. Protheragen’s biomarker discovery services utilize advanced molecular and cellular screening strategies to identify candidate biomarkers that are critical for Polycythemia Vera drug development. Our process encompasses high-throughput screening, literature mining, and data-driven validation to ensure the selection of biologically relevant and actionable biomarkers. Rigorous validation steps are integrated to confirm the specificity, sensitivity, and functional relevance of each candidate, supporting their application in preclinical therapeutic research.
Multi Omics: Leveraging cutting-edge genomics, transcriptomics, proteomics, and metabolomics technologies, Protheragen provides an integrated multi-omics approach to biomarker discovery and analysis. This comprehensive study of biological systems enables the identification of DNA variants, RNA transcripts, protein expression patterns, and metabolite profiles associated with Polycythemia Vera. Our multi-omics workflow facilitates the delineation of key disease pathways, such as JAK-STAT signaling, erythropoiesis regulation, and cytokine-mediated responses, offering a holistic view of disease mechanisms relevant to therapeutic development.
Candidate Validation: Candidate biomarker validation at Protheragen employs a suite of experimental and computational strategies to establish associations with Polycythemia Vera pathophysiology. Preliminary screening includes functional assays, pathway analysis, and cross-validation with disease models. Promising candidates are prioritized based on criteria such as biological relevance, reproducibility, detectability in relevant sample types, and alignment with known disease mechanisms. This systematic approach ensures that only high-potential biomarkers advance to assay development and further preclinical evaluation.
Diverse Technological Platforms: Protheragen offers custom assay development capabilities across a range of analytical platforms, ensuring adaptability to specific biomarker requirements. Our platforms include immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and advanced histopathology and imaging technologies. Each platform can be tailored to the unique analytical needs of Polycythemia Vera biomarker research, supporting both qualitative and quantitative studies.
Immunoassays: We develop and optimize ELISA, chemiluminescent, and multiplex immunoassays for sensitive and specific detection of protein biomarkers in various sample matrices.
Mass Spectrometry: Our LC-MS/MS platforms enable precise quantification and characterization of proteins, peptides, and metabolites, supporting both targeted and discovery-based analyses.
Flow Cytometry: Multiparametric flow cytometry assays are employed for cell surface and intracellular marker analysis, enabling high-throughput phenotyping and functional studies of hematopoietic and immune cell populations.
Molecular Diagnostics: We implement PCR, qPCR, and digital PCR methods for the detection of genetic variants, fusion transcripts, and gene expression changes associated with Polycythemia Vera.
Histopathology And Imaging: Advanced histopathology and imaging techniques, including immunohistochemistry and digital pathology, are utilized for tissue-based biomarker localization and quantification.
Rigorous Method Validation: All assay methods undergo rigorous validation in accordance with established guidelines for preclinical research. Validation parameters include specificity, sensitivity, linearity, reproducibility, and robustness. Comprehensive quality control measures are applied throughout the process to ensure data integrity and reliability, including the use of appropriate controls, reference standards, and replicates.
Protheragen’s quantitative analysis capabilities enable precise measurement of biomarker levels across diverse sample types. Our platforms support both absolute and relative quantification, facilitating comparative studies and longitudinal analyses essential for preclinical drug development. Robust data management and statistical analysis frameworks ensure accurate interpretation of results.
Sample Analysis: We handle a wide range of preclinical sample types, including blood, plasma, serum, bone marrow, tissue lysates, and cell cultures. Standardized protocols are implemented for sample collection, processing, storage, and analysis to maintain sample integrity. Quality assurance measures are embedded at each step to ensure the reliability and reproducibility of analytical results.
High Throughput Capabilities: Our high-throughput analytical platforms support multiplexed biomarker analysis, enabling simultaneous quantification of multiple targets within limited sample volumes. These capabilities enhance efficiency, reduce turnaround times, and conserve valuable preclinical samples, supporting large-scale studies and comprehensive biomarker profiling.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) | ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) encodes a ubiquitously expressed non-receptor tyrosine kinase that plays a critical role in various cellular processes. ABL1 is involved in the regulation of cell differentiation, division, adhesion, and stress response. The ABL1 protein localizes to both the nucleus and cytoplasm, where it interacts with numerous signaling and structural proteins. Its kinase activity is tightly regulated under normal physiological conditions, and it participates in pathways that control actin cytoskeleton dynamics, DNA damage response, and apoptosis. | ABL1 is widely used as a biomarker in the context of hematologic malignancies, most notably chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The BCR-ABL1 fusion gene, resulting from a reciprocal translocation between chromosomes 9 and 22 (the Philadelphia chromosome), produces a constitutively active tyrosine kinase that drives leukemogenesis. Detection of the BCR-ABL1 fusion transcript by molecular methods is employed for diagnosis, monitoring of minimal residual disease, and assessment of therapeutic response in affected patients. |
| BCR activator of RhoGEF and GTPase (BCR) | BCR (Breakpoint Cluster Region) encodes a multifunctional protein that acts as a GTPase-activating protein (GAP) for the small GTPase Rac and as a guanine nucleotide exchange factor (GEF) for RhoA. Through these activities, BCR regulates the cycling between active and inactive forms of Rac and RhoA, which are critical for controlling actin cytoskeleton organization, cell migration, and proliferation. BCR also possesses serine/threonine kinase activity and is involved in signaling pathways that influence cell growth and differentiation. The BCR gene is notable for its involvement in chromosomal translocations, particularly with ABL1 in the t(9;22)(q34;q11) translocation that generates the BCR-ABL fusion protein. | BCR is primarily applied as a biomarker in the context of hematological malignancies, especially chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL), due to its role in the BCR-ABL fusion gene. The detection of BCR-ABL transcripts is used in diagnosis, monitoring of minimal residual disease, and assessment of therapeutic response in these diseases. The presence and levels of BCR-ABL fusion transcripts, rather than wild-type BCR alone, are commonly measured in clinical practice. |
| Janus kinase 2 (JAK2) | Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase that plays a critical role in the signaling pathways of various cytokines and growth factors. Upon cytokine binding to their respective receptors, JAK2 becomes activated through phosphorylation and subsequently phosphorylates signal transducers and activators of transcription (STAT) proteins. This JAK-STAT signaling pathway regulates gene expression involved in processes such as hematopoiesis, immune function, cell growth, and differentiation. JAK2 is particularly important in the regulation of erythropoiesis and thrombopoiesis, as it mediates signaling for erythropoietin and thrombopoietin receptors. | JAK2 is used as a biomarker primarily in the context of myeloproliferative neoplasms (MPNs). The presence of the JAK2 V617F mutation is frequently detected in patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Detection of this mutation aids in the diagnosis and classification of these hematologic disorders. Additionally, JAK2 mutation testing can support disease monitoring and may inform therapeutic decision-making in clinical practice. |
| KIT proto-oncogene, receptor tyrosine kinase (KIT) | The KIT proto-oncogene encodes a type III receptor tyrosine kinase known as KIT (also called CD117). KIT is a transmembrane protein that binds stem cell factor (SCF), triggering receptor dimerization and autophosphorylation of intracellular tyrosine residues. This activation initiates multiple downstream signaling pathways, including PI3K/AKT, RAS/RAF/MEK/ERK, and JAK/STAT, which regulate cellular processes such as proliferation, survival, differentiation, and apoptosis. KIT plays a critical role in the development and maintenance of hematopoietic stem cells, melanocytes, germ cells, and interstitial cells of Cajal. | KIT is utilized as a biomarker in several clinical contexts. Immunohistochemical detection of KIT protein (CD117) is commonly employed in the diagnosis of gastrointestinal stromal tumors (GISTs), where KIT expression is frequently observed. KIT mutations are also detected in a subset of other malignancies, such as certain types of melanoma, acute myeloid leukemia, and mastocytosis, and can inform prognosis and therapeutic decisions. The presence or absence of KIT expression and mutations is used to help distinguish between tumor types and guide the use of targeted therapies. |
| MDM2 proto-oncogene (MDM2) | The MDM2 proto-oncogene encodes an E3 ubiquitin-protein ligase that plays a central role in regulating the p53 tumor suppressor pathway. MDM2 binds directly to the transactivation domain of the p53 protein, inhibiting its transcriptional activity and promoting its ubiquitination and subsequent proteasomal degradation. Through this negative feedback loop, MDM2 controls p53 protein levels and activity, thereby influencing cell cycle progression, DNA repair, and apoptosis. MDM2 itself is transcriptionally activated by p53, creating an autoregulatory feedback mechanism. In addition to p53, MDM2 interacts with other cellular proteins involved in cell proliferation and survival. | MDM2 is used as a biomarker in various clinical and research settings, particularly in oncology. Overexpression or amplification of MDM2 has been observed in several tumor types, including soft tissue sarcomas (such as well-differentiated and dedifferentiated liposarcomas), gliomas, and some leukemias. Detection of MDM2 gene amplification or protein overexpression can aid in the differential diagnosis of certain tumors, for example, distinguishing liposarcoma from other soft tissue neoplasms. Additionally, MDM2 status may be assessed to inform prognosis and guide therapeutic strategies, especially in the context of targeted therapies that disrupt the MDM2-p53 interaction. |
| MPL proto-oncogene, thrombopoietin receptor (MPL) | The MPL proto-oncogene encodes the thrombopoietin receptor (also known as CD110), which is a member of the type I cytokine receptor family. This receptor is primarily expressed on the surface of hematopoietic stem cells and megakaryocyte progenitor cells. Upon binding its ligand, thrombopoietin (TPO), MPL activates downstream signaling pathways, including the JAK-STAT, MAPK, and PI3K-AKT pathways. These signaling cascades promote the proliferation, differentiation, and survival of megakaryocytic lineage cells, leading to the production of platelets. MPL also plays a role in the maintenance of hematopoietic stem cell quiescence and self-renewal. | Mutations in the MPL gene have been identified in a subset of myeloproliferative neoplasms (MPNs), such as essential thrombocythemia and primary myelofibrosis. Detection of MPL mutations, particularly the W515L and W515K variants, is used in the molecular characterization of these disorders. Analysis of MPL mutation status can assist in the differential diagnosis of MPNs and may provide information relevant to prognosis and therapeutic decision-making. Additionally, MPL expression and mutation analysis are utilized in research and clinical settings to distinguish between different types of hematologic diseases. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, as well as other cell types including monocytes, dendritic cells, and epithelial cells. IL1B is synthesized as an inactive precursor (pro-IL1B) and is cleaved by caspase-1 to generate the active form. It plays a central role in the regulation of immune and inflammatory responses by inducing the expression of adhesion molecules, chemokines, and other cytokines. IL1B contributes to fever induction, leukocyte recruitment, and the activation of lymphocytes. It also influences cell proliferation, differentiation, and apoptosis in various tissues. | IL1B has been widely studied as a biomarker for inflammation and immune activation. Elevated levels of IL1B in serum, plasma, or tissue samples have been associated with a range of inflammatory and infectious diseases, including rheumatoid arthritis, sepsis, inflammatory bowel disease, and certain autoinflammatory syndromes. Measurement of IL1B concentrations is used in research and clinical studies to assess the extent of inflammatory activity and to monitor responses to anti-inflammatory therapies. |
| microRNA 451a (MIR451A) | microRNA 451a (MIR451A) is a small non-coding RNA molecule that functions primarily in the post-transcriptional regulation of gene expression. It is processed from a precursor transcript into a mature miRNA, which is incorporated into the RNA-induced silencing complex (RISC). MIR451A binds to complementary sequences in the 3' untranslated regions (3' UTRs) of target messenger RNAs (mRNAs), leading to mRNA degradation or translational repression. MIR451A has been implicated in the regulation of cellular processes such as proliferation, apoptosis, differentiation, and stress response. It is notably involved in erythropoiesis, where it contributes to the maturation of erythroid cells, and has also been studied in the context of cellular responses to oxidative stress and metabolic regulation. | MIR451A has been investigated as a biomarker in various clinical contexts, particularly in oncology and hematology. Altered expression levels of MIR451A have been reported in several types of cancer, including gastric, colorectal, lung, and breast cancers, where its expression pattern may correlate with disease progression, prognosis, or therapeutic response. In addition, MIR451A is detectable in body fluids such as blood plasma and serum, supporting its potential utility as a minimally invasive biomarker. Studies have also explored its application in monitoring hemolytic diseases and neurological disorders. Its stability in extracellular vesicles, such as exosomes, further supports its use in liquid biopsy approaches. |
| transforming growth factor beta 1 (TGFB1) | Transforming growth factor beta 1 (TGFB1) is a multifunctional cytokine belonging to the TGF-β superfamily. It is involved in the regulation of numerous cellular processes, including cell proliferation, differentiation, apoptosis, and extracellular matrix production. TGFB1 plays a critical role in immune regulation by modulating the activity of various immune cells, such as T cells, B cells, macrophages, and dendritic cells. It is also a key mediator in tissue remodeling and wound healing, primarily through its effects on fibroblast activation and collagen synthesis. Dysregulation of TGFB1 signaling has been implicated in the pathogenesis of fibrosis, cancer, and several chronic inflammatory diseases. | TGFB1 has been utilized as a biomarker in various clinical and research settings. Its expression levels in tissues, blood, or other bodily fluids have been associated with disease activity or progression in conditions such as fibrotic disorders (e.g., pulmonary fibrosis, liver fibrosis), certain cancers, and autoimmune diseases. Measurement of TGFB1 can provide information related to disease state, prognosis, or response to therapy. For example, elevated TGFB1 levels have been observed in patients with active fibrosis and have been studied in the context of tumor microenvironment characterization in oncology. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF), also known as TNF-alpha, is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as other immune cells such as T lymphocytes and natural killer cells. TNF plays a central role in the regulation of immune responses, inflammation, and apoptosis. It is involved in the activation of signaling pathways that lead to the expression of other inflammatory mediators, recruitment of immune cells to sites of infection or injury, and the induction of cell death in certain cell types. TNF is also implicated in the pathogenesis of various inflammatory and autoimmune diseases due to its potent effects on immune cell activation and cytokine production. | TNF is measured in biological fluids such as serum, plasma, or synovial fluid to assess the presence and extent of inflammation. Elevated TNF levels have been observed in conditions such as rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain cancers. Its quantification can aid in evaluating disease activity, monitoring response to anti-TNF therapies, and providing supportive information for the diagnosis or prognosis of inflammatory disorders. |
Explore Research Opportunities with Protheragen. Our biomarker research services provide a comprehensive suite of analytical and discovery capabilities for Polycythemia Vera, supporting preclinical drug development and mechanistic studies. All biomarkers discussed are considered research targets only; we do not claim any as validated or mandatory for any application. Our focus is strictly on exploratory research within preclinical stages, maintaining scientific objectivity and rigor throughout all projects.
We invite you to engage with Protheragen for collaborative discussions on exploratory biomarker research in Polycythemia Vera. Our team is dedicated to advancing scientific knowledge through objective, preclinical research partnerships. Connect with us to explore opportunities for scientific collaboration and knowledge exchange.
Make Order
Experimental Scheme
Implementation
Conclusion
